Log in

Pulmonx Stock Forecast, Price & News

-1.00 (-2.32 %)
(As of 10/30/2020 12:00 AM ET)
Today's Range
Now: $42.06
50-Day Range N/A
52-Week Range
Now: $42.06
Volume275,004 shs
Average Volume248,534 shs
Market Capitalization$1.43 billion
P/E RatioN/A
Dividend YieldN/A
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in Europe, the Middle East, Africa, the Asia-Pacific, the United States, and internationally. Pulmonx Corporation was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.32 out of 5 stars

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:LUNG



Sales & Book Value

Annual SalesN/A



Market Cap$1.43 billion
Next Earnings Date11/10/2020 (Confirmed)
OptionableNot Optionable
-1.00 (-2.32 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LUNG News and Ratings via Email

Sign-up to receive the latest news and ratings for LUNG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Pulmonx (NASDAQ:LUNG) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Pulmonx?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmonx in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Pulmonx

When is Pulmonx's next earnings date?

Pulmonx is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Pulmonx

How can I listen to Pulmonx's earnings call?

Pulmonx will be holding an earnings conference call on Tuesday, November 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for LUNG?

5 Wall Street analysts have issued 1 year price targets for Pulmonx's shares. Their forecasts range from $44.00 to $50.00. On average, they anticipate Pulmonx's stock price to reach $47.80 in the next year. This suggests a possible upside of 13.6% from the stock's current price.
View analysts' price targets for Pulmonx

Who are some of Pulmonx's key competitors?

Who are Pulmonx's key executives?

Pulmonx's management team includes the following people:
  • Mr. Glendon E. French, CEO, Pres, Sec. & Director (Age 58, Pay $576.16k)
  • Dr. Derrick Sung, Chief Financial Officer (Age 47, Pay $242.3k)
  • Mr. Geoffrey Beran Rose, Chief Commercial Officer (Age 47, Pay $336.14k)
  • Mr. Sri Radhakrishnan, Chief Technical Officer
  • Mr. Martin Schneider, VP of Fin. and Admin. (Age 60)

When did Pulmonx IPO?

(LUNG) raised $100 million in an IPO on Thursday, October 1st 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers.

What is Pulmonx's stock symbol?

Pulmonx trades on the NASDAQ under the ticker symbol "LUNG."

When does the company's quiet period expire?

Pulmonx's quiet period expires on Tuesday, November 10th. Pulmonx had issued 10,000,000 shares in its public offering on October 1st. The total size of the offering was $190,000,000 based on an initial share price of $19.00. During the company's quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Pulmonx?

Shares of LUNG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pulmonx's stock price today?

One share of LUNG stock can currently be purchased for approximately $42.06.

How big of a company is Pulmonx?

Pulmonx has a market capitalization of $1.43 billion. Pulmonx employs 202 workers across the globe.

What is Pulmonx's official website?

The official website for Pulmonx is pulmonx.com.

How can I contact Pulmonx?

The company can be reached via phone at 650-364-0400.

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.